Dajun Yang

Chairman and CEO at Ascentage Pharma

Dajun Yang is the Chairman and CEO of Ascentage Pharma, concurrently served as professor and Ph.D. supervisor of Sun Yat-sen University Cancer Center. Dr. Yang devotes himself to apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made a major breakthrough in the field of new target drug R&D for apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs covering multiple targets in this field. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as National High-tech R&D Program (863 Program) and Major innovative drug Developments. Dr. Yang leads the team to win the awards such as Jiangsu Major Innovation Team and Suzhou 2018 Major Innovation Team, the First Jiangsu Innovation Competition Team Award, and R&D Achievement of the Year 2017 from the BayHelix Group. He has extensive influence in the field of innovative drug R&D.